An interventional, single arm, multicenter, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-CVU on wound healing of chronic venous ulcer (CVU).

RHEACELL GmbH & Co. KG0 个研究点目标入组 37 人开始时间: 2017年3月13日最近更新: 2020年8月25日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: RHEACELL GmbH & Co. KG
入组人数: 37

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Male or female patients aged 35 to 85 years;
•2. Chronic venous leg ulcer (as defined by the current AWMF guidelines: therapy resistant ulcer that shows no improvement within 3 months despite of optimal phlebological therapies or is not healed within 12 months) diagnosed by doppler ultrasonography (DUS), ankle brachial index (ABI, 0.9–1.3), physical examination and dermatological review;
•3. Wound size of target ulcer between 1.5 and 100 cm2 measured by a standardized photography at the screening visits (Visit 1 and Visit 2);
•4. Wound location below knee;
•5. If patients are suffering from 2 or more ulcers at the same extremity, the target ulcer has to be separated by a minimum bridge of 1 cm of epithelialized skin from other ulcers (the largest ulcer should be the target ulcer, if not decided otherwise at discretion of the investigator; the target ulcer is defined at Visit 1);
•6. Body mass index (BMI) between 20 and 45 kg/m²;
•7. Patients understand the nature of the procedure and are providing written informed consent prior to any clinical trial procedure;
•8. Women of childbearing potential must have a negative blood pregnancy test at Visit 1
•9. Women of childbearing potential and their partner must be willing to use highly effective contraceptive methods during the course of the clinical trial.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 10
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 27

排除标准

•1. Evidence of the ulcer extending to the underlying muscle, tendon, or bone;
•2. Current use of systemic steroid medication above Cushing threshold dose (>7.5 mg/d prednisone or equivalent);
•3. Diabetes mellitus that has to be evaluated by blood test (Haemoglobin A1c [HbA1c] >7.5%);
•4. Peripheral Artery Disease (PAD) including claudication with need of treatment;
•5. Acute deep vein thrombosis (maximum 30 days from diagnosis) or a still untreated deep vein thrombosis;
•6. Unable to tolerate leg ulcer compression bandage;
•7. Infection of the target ulcer requiring treatment as judged clinically;
•8. Any chronic dermatological disorders diagnosed at the investigator’s discretion;
•9. Skin disorders, unrelated to the ulcer, that are present adjacent to the target wound;
•10. Current use of medications that influence wound healing: systemic immunosuppressives, cytotoxic medicinal products, and systemic steroids (above Cushing-threshold level);
•11. Known abuse of alcohol, drugs, or medicinal products;
•12. Cancerous or pre-cancerous lesions adjacent to the target wound;
•13. Patients anticipated to be unwilling or unable to comply with the requirements of the protocol;
•14. Pregnant or lactating women;
•15. Systemic infectious disease diagnosed by serology testing for human immunodeficiency virus (HIV?1, HIV-2);
•16. Any known allergies to components of the IMP;
•17. Prior surgical procedures such as bypass or mesh-graft treatment within 2 months prior to Visit 1;
•18. Patients with significant ulcer healing or wound size enlargement of more than 25% at Visit 2 compared to Visit 1;
•19. Treatment of target ulcer with active wound care agents (e.g. iruxol, local antibiotics or silver dressings), which have not been paused 14 days before IMP application;
•20. Current or previous (within 30 days of enrollment) treatment with another IMP, or participation and/or under follow-up in another clinical trial;
•21. Previous participation in this clinical trial (except for screening failures due to an inclusion or exclusion criterion);
•22. Evidence of any other medical conditions (such as psychiatric illness, physical examination, or laboratory findings) that may interfere with the planned treatment, affect the patient’s compliance, or place the patient at high risk of complications related to the treatment;
•23. Employees of the sponsor, or employees or relatives of the investigator.

研究者

发起方

RHEACELL GmbH & Co. KG

相似试验

进行中（未招募）

1 期

Clinical trial to investigate the efficacy and safety of allo-APZ2-ACLF administered intravenously to patients suffering from acute-on-chronic liver failure.MedDRA version: 20.0Level: PTClassification code 10077305Term: Acute on chronic liver failureSystem Organ Class: 10019805 - Hepatobiliary disordersAcute-on-Chronic Liver Failure

EUCTR2018-001240-61-DERHEACELL GmbH & Co. KG18

进行中（未招募）

1 期

EUCTR2018-001240-61-ATRHEACELL GmbH & Co. KG40

进行中（未招募）

1 期

Study to investigate the efficacy and safety of allo-APZ2-EB on wound healing of epidermolysis bullosa (EB)

EUCTR2018-001009-98-DERHEACELL GmbH & Co. KG16

进行中（未招募）

1 期

Study to investigate the efficacy and safety of allo-APZ2-EB on wound healing of epidermolysis bullosa (EB)Recessive dystrophic epidermolysis bullosa (RDEB)MedDRA version: 20.0Level: PTClassification code 10014989Term: Epidermolysis bullosaSystem Organ Class: 10010331 - Congenital, familial and genetic disorders

EUCTR2018-001009-98-ITRHEACELL GmbH & Co. KG18

进行中（未招募）

1 期

EUCTR2018-001009-98-GBRHEACELL GmbH & Co. KG16